Evidence map›Paper›PMID 39370151›Full record

ArticleNephrology (Carlton, Vic.)2024

Structures for quality assurance and measurements for kidney replacement therapies: A multinational study from the ISN-GKHA.

Udeme E Ekrikpo, Bianca Davidson, Viviane Calice-Silva, Sabine Karam, Mohamed A Osman, Silvia Arruebo, Fergus J Caskey, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Nephrology (Carlton, Vic.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Udeme E EkrikpoDepartment of Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.ORCID https://orcid.org/0000-0002-3911-5564
Bianca DavidsonDivision of Nephrology and Hypertension, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Viviane Calice-SilvaPro-Rim Foundation, Joinville, Santa Catarina, Brazil.ORCID https://orcid.org/0000-0002-9696-0529
Sabine KaramDivision of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Mohamed A OsmanDepartment of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Silvia ArrueboThe International Society of Nephrology, Brussels, Belgium.
Fergus J CaskeyPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Sandrine DamsterThe International Society of Nephrology, Brussels, Belgium.
Jo-Ann DonnerThe International Society of Nephrology, Brussels, Belgium.
Vivekanand JhaGeorge Institute for Global Health, New Delhi, India.
Adeera LevinDivision of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Syed SaadDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Marcello TonelliDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
Feng YeDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Ikechi G OkpechiDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID https://orcid.org/0000-0002-6545-9715
Aminu K BelloDivision of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
David W JohnsonDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Funding

International Society of Nephrology RES0033080
6 · The paper itself

Abstract

aimOptimal care for patients with kidney failure reduces the risks of adverse health outcomes, including cardiovascular events and death. We evaluated data from the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to assess the capacity for quality service delivery for kidney failure care across countries and regions.

methodWe explored the quality of kidney failure care delivery and the monitoring of quality indicators from data provided by an international survey of stakeholders from countries affiliated with the ISN from July to September 2022.

resultsOne hundred and sixty seven countries participated in the survey, representing about 97.4% of the world's population. In countries where haemodialysis (HD) was available, 81% (n = 134) provided standard HD sessions (three times weekly for 3-4 h per session) to patients. Among countries with peritoneal dialysis (PD) services, 61% (n = 101) were able to provide standard PD care (3-4 exchanges per day). In high-income countries, 98% (n = 62) reported that >75% of centers regularly monitored dialysis water quality for bacteria compared to 28% (n = 5) of low-income countries (LICs). Capacity to monitor the administration of immunosuppression drugs was generally available in 21% (n = 4) of LICs, compared to 90% (n = 57) of high-income countries. There was significant variability between and within regions and country income groups in reporting the quality of services utilized for kidney replacement therapies.

conclusionQuality assurance standards on diagnostic and treatment tools were variable and particularly infrequent in LICs. Standardization of delivered care is essential for improving outcomes for people with kidney failure.

Indexed as

Quality Assurance, Health CareQuality Indicators, Health CareGlobal HealthHumansKidney Failure, ChronicNephrologyRenal DialysisRenal Replacement TherapyhaemodialysisISN regionskidney replacement therapykidney transplantationperitoneal dialysisquality

Identifiers

PMID39370151
PMCPMC13546963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.